Vendor, Boulder, CO
Crestone, Inc.
UEI EDSLAP2J1BL8, CAGE 5RDJ6
2 awards and $4,667,159 obligated between January 7, 2026 and August 31, 2026, 100% under full and open competition, against 12.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 2 |
| Definitive Contract | 2 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N93020C00020Definitive Contract, January 7, 2026, Full and Open Competition, 12 offers | National Institutes of Health NiaidNational Institutes of Health | To Advance a Promising, Small-Molecule Compound CRS0540 to Ind Filing and Through Phase I Clinical Studies.NAICS 541715, PSC AN12 | $3,501,414 |
| 75N93019C00056Definitive Contract, May 18, 2026, Full and Open Competition, 12 offers | National Institutes of Health NiaidNational Institutes of Health | To Perform the Evaluation of Safety and Efficacy of CRS3123 to Treat Clostridium Difficile Infections.NAICS 541714, PSC AN12 | $1,165,745 |
- Places of performance
- Colorado
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 7 across 2 awards